tiprankstipranks
Faron Pharmaceuticals Oy (GB:FARN)
LSE:FARN
Holding GB:FARN?
Track your performance easily

Faron Pharmaceuticals Oy (FARN) Income Statement

29 Followers

Faron Pharmaceuticals Oy Income Statement

Last quarter (Q4 2022), Faron Pharmaceuticals Oy's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, Faron Pharmaceuticals Oy's net income was €―. See Faron Pharmaceuticals Oy’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-€ 803.00K---€ 19.00K
Cost of Revenue
------
Gross Profit
-€ 803.00K----
Operating Expense
-€ 28.23M€ 21.11M€ 16.65M€ 13.10M€ 19.67M
Operating Income
-€ -27.43M€ -21.11M€ -16.65M€ -13.10M€ -19.65M
Net Non Operating Interest Income Expense
-€ -1.35M€ 245.00K€ 53.00K€ 158.00K€ -123.00K
Other Income Expense
------
Pretax Income
-€ -28.73M€ -21.18M€ -16.93M€ -13.25M€ -20.08M
Tax Provision
--€ 16.00K€ 10.00K€ 11.00K€ 2.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ -28.73M€ -21.19M€ -16.94M€ -13.26M€ -20.09M
Basic EPS
-€ -0.52€ -0.42€ -0.37€ -0.31€ -0.65
Diluted EPS
-€ -0.52€ -0.42€ -0.37€ -0.31€ -0.65
Basic Average Shares
-€ 55.23M€ 50.72M€ 45.71M€ 35.53M€ 30.75M
Diluted Average Shares
-€ 55.23M€ 50.72M€ 45.71M€ 35.53M€ 30.75M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-€ 28.23M€ -21.11M€ -16.65M€ -13.10M€ 19.67M
Net Income From Continuing And Discontinued Operation
-€ -28.73M€ -21.19M€ -16.94M€ -13.26M€ -20.09M
Normalized Income
-€ -23.27M€ -17.15M€ -13.72M€ -10.73M€ -19.82M
Interest Expense
-----€ 121.00K
EBIT
-€ -27.35M€ -20.96M€ -16.79M€ -13.10M€ -19.96M
EBITDA
-€ -27.05M€ -20.96M€ -16.79M€ -13.10M€ -19.86M
Currency in EUR

Faron Pharmaceuticals Oy Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis